Daniel Bendheim - Phibro Animal President
PB8 Stock | EUR 20.20 0.40 1.94% |
President
Mr. Daniel M. Bendheim serves as Executive Vice President, Director, Corporationrationrate Strategy of the company. He was elected as a director of Phibro in November 2013. Prior to joining us, He worked as an analyst at South Coast Capital, a boutique investment bank. Mr. Bendheim obtained a B.A. degree in political science with honors from Yeshiva University in 1993 and a J.D. degree with honors from Harvard Law School in 1996. He is a manager of BFI with respect to certain economic rights pertaining to shares of our stock owned by BFI. Mr. Bendheim is qualified to serve on our Board of Directors due to his extensive management experience in all facets of the animal health, mineral nutrition and performance products businesses during his tenure with the Company and his management role within BFI. since 2014.
Age | 51 |
Tenure | 11 years |
Phone | 201 329 7300 |
Web | https://www.pahc.com |
Daniel Bendheim Latest Insider Activity
Tracking and analyzing the buying and selling activities of Daniel Bendheim against Phibro Animal stock is an integral part of due diligence when investing in Phibro Animal. Daniel Bendheim insider activity provides valuable insight into whether Phibro Animal is net buyers or sellers over its current business cycle. Note, Phibro Animal insiders must abide by specific rules, including filing SEC forms every time they buy or sell Phibro Animal'sshares to prevent insider trading or benefiting illegally from material non-public information that their positions give them access to.
Daniel Bendheim over six months ago Disposition of 2500 shares by Daniel Bendheim of Phibro Animal at 11.83 subject to Rule 16b-3 |
Phibro Animal Management Efficiency
The company has return on total asset (ROA) of 0.0532 % which means that it generated a profit of $0.0532 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.1428 %, meaning that it generated $0.1428 on every $100 dollars invested by stockholders. Phibro Animal's management efficiency ratios could be used to measure how well Phibro Animal manages its routine affairs as well as how well it operates its assets and liabilities.Management Performance
Return On Equity | 0.14 | |||
Return On Asset | 0.0532 |
Phibro Animal Health Leadership Team
Elected by the shareholders, the Phibro Animal's board of directors comprises two types of representatives: Phibro Animal inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Phibro. The board's role is to monitor Phibro Animal's management team and ensure that shareholders' interests are well served. Phibro Animal's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Phibro Animal's outside directors are responsible for providing unbiased perspectives on the board's policies.
Ramon Fuenmayor, Pres Region | ||
Larry Miller, Chief Operating Officer | ||
Thomas Dagger, Senior Vice President General Counsel, Corporate Secretary | ||
Jonathan Bendheim, Director and President MACIE Region and General Manager of Israel Operations | ||
E Corcoran, Independent Director | ||
Damian Finio, Chief Officer | ||
Jean Filippi, Pres Region | ||
Richard Johnson, Chief Financial Officer | ||
Gerald Carlson, Independent Director | ||
Mary Malanoski, Independent Director | ||
Rob Aukerman, President North America Region | ||
Jack Bendheim, Chairman of the Board, President, Chief Executive Officer, Director | ||
Daniel Bendheim, Executive Vice President, Corporate Strategy and Director | ||
Anthony Andolino, Vice President - Finance, Treasurer | ||
Sam Gejdenson, Independent Director | ||
Lisa Escudero, Senior Vice President of Human Resources | ||
Carol Wrenn, Independent Director |
Phibro Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Phibro Animal a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.14 | |||
Return On Asset | 0.0532 | |||
Profit Margin | 0.04 % | |||
Operating Margin | 0.08 % | |||
Current Valuation | 977.72 M | |||
Shares Outstanding | 20.34 M | |||
Shares Owned By Insiders | 0.54 % | |||
Shares Owned By Institutions | 99.46 % | |||
Price To Earning | 21.51 X | |||
Price To Book | 2.32 X |
Currently Active Assets on Macroaxis
Additional Information and Resources on Investing in Phibro Stock
When determining whether Phibro Animal Health offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Phibro Animal's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Phibro Animal Health Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Phibro Animal Health Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Phibro Animal Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors. You can also try the Positions Ratings module to determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance.